Doxorubicin, Cyclophosphamide followed by Paclitaxel vs. 5-FU, Doxorubicin, Cyclophosphamide in locally advanced Breast Cancer

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20170711001

Enrollment

154

Registered

2017-07-11

Start date

2017-07-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced breast cancer

Interventions

4 cycles of AC (Doxorubicin&#45

60 mg/m2 Cyclophosphamide&#45

600 mg/m2) in day 1

3 weekly cycle followed by postoperative 4 cycles of Paclitaxel (175 mg/m2) ,3 cycles of FAC (5&#45

Flurouracil&#45

500 mg/m2&#44

Doxorubicin&#45

50 mg/m2&#44

Cyclophosphamide â€“ 500 mg/m2) in day 1

3 weekly cycle followed by postoperative 3 cycles of FAC

Active Comparator Drug,Active Comparator Drug

Doxorubicin&#44

Cyclophosphamide followed by Paclitaxel,5&#45

FU&#44

Cyclophosphamide

Eligibility

Sex/Gender

Female

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients willing to be included in this study. ï‚· Histopathologically proven invasive ductal carcinoma. ï‚· No prior chemotherapy, radiotherapy or breast surgery. ï‚· Patients are required to have Eastern Co-operative Oncology Group (ECOG) performance status up to scale 2. ï‚· Female sex. ï‚· Patients without distant metastasis.

Exclusion criteria

Exclusion criteria: Pregnant or lactating woman. ï‚· Patients dropped out or lost to follow up before completion of study. ï‚· Serious concomitant medical illness including severe heart disease, uncontrolled diabetes mellitus, or hypertension. ï‚· Life expectancy < 6 months. ï‚· Male sex. ï‚· Initial surgery (excluding diagnostic biopsy) of the primary site. ï‚· Patients with distant metastasis. ï‚· Patients with double primaries.

Design outcomes

Primary

Measure	Time frame
Response Before surgery and end of chemotherapy RECIST criteria	—

Secondary

Measure	Time frame
Toxicity After each cycle of chemotherapy The National Cancer Instituteâ€˜s â€—Common Terminology Criteria for Adverse Events, v.3.0â€˜	—

Countries

Bangladesh

Contacts

Public ContactShahed Matin

Bangabandhu Sheikh Mujib Medical University

md.shahed.ul.matin@gmail.com01747712152

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Doxorubicin&#44; Cyclophosphamide followed by Paclitaxel vs. 5&#45;FU&#44; Doxorubicin&#44; Cyclophosphamide in locally advanced Breast Cancer